The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 40 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, this category of minimal residual disease status has not been examined to date in patients with relapsed or refractory multiple myeloma, in part because of limited availability of data showing a correlation between depth of response and survival outcomes in patients at this stage of the disease.7”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The “Relapsed and/or refractory” section (page unavailable) says data linking depth of response to outcomes are limited, supporting the citing sentence’s rationale. The “Redefining CR” section discusses minimal residual disease (MRD) studies in newly diagnosed patients, but does not state that MRD status had never been examined in relapsed or refractory patients. The relapsed-setting section’s “MR” means minimal response, not minimal residual disease. (LLM, conf=0.78)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As in our trial (POLLUX), the addition of daratumumab to a standard-of-care regimen of bortezomib and dexamethasone in the CASTOR trial was associated with a significantly lower risk of disease progression or death.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
What the sources say
- Supportedcites [18] source
The Trial Treatments section (p. 3) confirms that CASTOR compared daratumumab plus bortezomib and dexamethasone with bortezomib and dexamethasone alone. The Discussion (p. 11) reports significantly longer progression-free survival and a 61.4% lower risk of disease progression or death in the daratumumab group. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [27] source
- Supportedcites [28] source
The Safety section identifies thrombocytopenia, gastrointestinal events, and rash as adverse events observed with lenalidomide-dexamethasone, and describes management of gastrointestinal events with supportive therapy and dose adjustment. This supports the part of the sentence attributed to this paper: the known toxic effects of lenalidomide-dexamethasone. The daratumumab-specific part has separate citations and is not attributed to this source. (LLM, conf=0.90)
- Supportedcites [30] source
This citation is attached to the known toxic effects of lenalidomide and dexamethasone, not to the daratumumab-specific part of the sentence. The Randomization and Study Treatment section identifies a lenalidomide–dexamethasone control group, and the Safety section and Table 3 report its adverse events. The paper does not assess the daratumumab combination. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [31] source
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
This source is cited for the known toxic effects of daratumumab, not for the safety of the three-drug combination. The Safety section (p. 5) reports that most adverse events with daratumumab were grade 1 or 2, and the Discussion (p. 11) describes an acceptable safety profile and mostly mild infusion-related reactions. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were observed in the intentionto-treat population (Table S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with the higher rates of deeper responses in the daratumumab group, the rate of results below the threshold for minimal residual disease was significantly higher in the daratumumab group than in the control group (by 3 to 5 times) at all evaluated thresholds (1 tumor cell per 10 4 , 10 5 , and 10 6 white cells) (Fig. S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the interim analysis, a total of 75 deaths had been observed (30 patients in the daratumumab group and 45 in the control group) (Table S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%,P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
- Also stated in: § Efficacy · plain
“the rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression-free survival was similarly prolonged in the daratumumab group among patients who had previous exposure to lenalidomide and those who had no previous exposure, as compared with the control group (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached (95% CI, could not be estimated) in the daratumumab group, as compared with 18.4 months (95% CI, 13.9 to could not be estimated) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with a partial response or better, the rate of progression-free survival at 12 months was 87.8% (95% CI, 83.1 to 91.3) in the daratumumab group versus 73.6% (95% CI, 67.0 to 79.1) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [8] source
The Ab generation section states that all antibodies described, including daratumumab, were human IgG1, κ antibodies. The Discussion identifies daratumumab as a human IgG1 antibody that binds CD38. The later phase 1–2 efficacy claims carry separate citations and are not attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria (see the Supplementary Appendix).20,21 This algorithm previously showed very strong concordance with independent reviews in a phase 2 study”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [9] source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase 3 trial of bortezomib and dexamethasone, with or without daratumumab, met its primary end point at the interim analysis and showed a significantly higher rate of progression-free survival, with a 61% lower risk of progression or death in the daratumumab group than in the control group.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [18] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [32] Chari A, 2015, Blood sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group.20,21”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Supportedcites [21] source
The Response criteria section recommends using the IMWG uniform response criteria in clinical trials and says the panel endorsed their response definitions. The citation therefore supports the identification of the criteria used; it does not independently document how the citing study assessed response. (LLM, conf=0.93)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab interferes with laboratory-based bloodcompatibility tests, including indirect Coombs' test, because of binding to CD38 on red cells.26”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
What the sources say
- Supportedcites [26] source
The Discussion says daratumumab interferes with blood compatibility testing because it binds directly to CD38 on red cells. The “DARA causes plasma panreactivity in vitro” section reports panreactivity at the antihuman globulin phase, supporting the reference to the indirect Coombs test. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, in the time-toevent analysis of disease progression, a total of 148 events (in 44 patients [15.4%] in the daratumumab group vs. 104 [36.7%] in the control group) were observed (hazard ratio, 0.34; 95% CI, 0.23 to 0.48; P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
- Also stated in: § Patients who have very good partial responses · plain
“The rates of treatment discontinuation owing to adverse events were low and similar in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Patients who have very good partial responses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment effect of daratumumab was consistent regardless of previous exposure to lenalidomide (a limitation being the relatively small number of patients with previous exposure to lenalidomide) and across all subgroups, including patients 65 years of age or older, those with disease that was refractory to proteasome inhibitors or the most recent line of therapy, those with International Stag”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although higher rates of neutropenia and infusion-related reactions (primarily during the first infusion) were observed with this combination than with lenalidomide and dexamethasone alone, these events did not result in higher rates of treatment discontinuation or death.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After continued treatment, responses deepened, with a rate of complete response or better that was twice as high with daratumumab as with the backbone regimen alone.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These reactions were mostly of grade 1 or 2; a total of 15 patients (5.3%) had grade 3 infusion reactions, and no patient had an event of grade 4 or 5.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 15Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall response No. with response 261 211 -Rate -% (95% CI) 92.9 (89.2-95.6)76.4 (71.0-81.3)<0.001”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 48.8% of the patients in the daratumumab group and in 42.0% of those in the control group, among which pneumonia was the most common (in 8.1% of the patients in the daratumumab group and in 8.5% of those in the control group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rate of infection of grade 3 or 4 was also slightly higher in the daratumumab group than in the control group (28.3% and 22.8%, respectively); the most common infection of grade 3 or 4 was pneumonia, which occurred at similar rates in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events leading to death were acute kidney injury (in 0.4% of the patients in the daratumumab group and in 1.1% in the control group), septic shock (in 1.1% and 0.4%, respectively), and pneumonia (in 0.7% in each group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 11Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“incidences of grade 3 or 4 diarrhea, fatigue, nausea, and dyspnea were slightly higher in the daratumumab group than in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stringent complete response § 51 (18.1) 20 (7.2) -”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of daratumumab infusionrelated reactions of any grade was 47.7%, with 92% of the reactions occurring during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events (in ≥1% of the patients in either group) that led to the discontinuation of treatment included pneumonia (in 1.1% of the patients in the daratumumab group and in 0.7% of those in the control group), pulmonary embolism (in 1.1% in the control group), and deterioration in general physical health (in 1.1% in the daratumumab group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite higher rates of neutropenia in the daratumumab group, the rate of infection of grade 3 or 4 was only slightly higher in the daratumumab group than in the control group (28% vs. 23%).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the CASTOR trial, 18 the addition of daratumumab to the backbone regimen in our trial resulted in a significantly higher rate of overall response, deeper responses, and longer duration of response.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common infusion-related reactions were cough (in 8.5% of the patients), dyspnea (in 8.5%), and vomiting (in 5.7%) (Table S5 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A phase 1-2 study of daratumumab, lena-lidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma showed that this combination provided therapeutic benefits, no dose-limiting toxic effects, and an 81% rate of overall response, including a 25% rate of stringent complete response”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The group-sequential design had one planned interim analysis to evaluate the primary end point.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“he incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, [1][2][3]”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [1][2][3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was approved by the independent ethics committee or institutional review board at each site before the initiation of the trial.Patients provided written informed consent, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and current International Conference on Harmonisation Good Clinical Practice guidelines.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Trial Design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee was established to periodically review unblinded safety data.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“At 18 months, the rate of progression-free survival was 72%, and the rate of overall survival was 90%.19”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We calculated that approximately 560 patients with 295 events (disease progression or death) would be needed to provide the trial with 85% power to detect a 30% lower risk of disease progression or death (hazard ratio, 0.70), using a log-rank test, with an overall two-sided significance level of 0.05.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that results below the threshold for minimal residual disease also should be a treatment goal in the context of relapsed or refractory disease.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 2. Prespecified Subgroup Analyses.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Shown are the results of the Kaplan-Meier analysis of progression-free survival among patients in the intention-totreat population, which included all patients who underwent randomization.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
Relapse can occur even after standard complete remission in the context of first-line therapy.
“Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative””
The paper relies on this without support.
The combination of lenalidomide and dexamethasone is an appropriate standard control regimen for patients with relapsed or refractory multiple myeloma who have received one or more previous lines of therapy.
“we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group).”
The paper relies on this without support.
The open-label design does not bias the assessment of progression-free survival.
“In this randomized, open-label, multicenter, phase 3 trial, we assigned patients who had relapsed or refractory multiple myeloma and had received one or more lines of previous therapy to receive either daratumumab, lenalidomide, and dexamethasone (daratumumab group) or lenalidomide and dexamethasone (control group).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a receptor highly expressed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Response rates to single-agent lenalidomide have consistently been surpassed by those achieved with doublet or triplet combinations, which has been taken as evidence for synergistic activity of this agent with other anti-myeloma agents48.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Control-group adverse-event discontinuation rates differ
MinorThe results give 8.2% of control-group patients as discontinuing treatment because of adverse events, but the safety section gives 7.8% for adverse events leading to treatment discontinuation. The text does not explain the difference.
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%)”
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationKumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Krejcik J, Blood
- Plesner T, Blood
Cited by
Sorted by citations
Items 301–400 of 1,433
Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
Ho, M., McCann, A. H., Bianchi, G., Zhang, L., Dowling, P., Bazou, D., O’Gorman, P., & Anderson, K. C. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1337115 · Cited by 38
“In particular, three-drug regimens incorporating daratumumab, with either bortezomib and dexamethasone or lenalidomide and dexamethasone showed unprecedented results in phase-III trials in RR MM with circa 60% reduction in risk of death or progression compared to the control arm [98,99].”
BackgroundDaratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0837-7 · Cited by 38
“5 months), daratumumab plus lenalidomide and dexamethasone recipients had significantly longer median PFS than lenalidomide plus dexamethasone recipients, with a 63% lower risk of disease progression or death (Table 1) [23].”
BackgroundMethodInfluentialSafety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma
Rocchi, S., Tacchetti, P., Pantani, L., Mancuso, K., Zannetti, B. A., Cavo, M., & Zamagni, E. (2018) · Haematologica · doi:10.3324/haematol.2018.191122 · Cited by 39
Measurable residual disease in multiple myeloma: ready for clinical practice?
Burgos, L., Puig, N., Cedena, M., Mateos, M., Lahuerta, J. J., Paiva, B., & Miguel, J. F. S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00911-4 · Cited by 41
“POLLUX (NCT02076009) [30] DRd vs Rd DRd: median PFS NR Rd: median PFS 17.”
BackgroundSelf-citationMinnix, M., Adhikarla, V., Caserta, E., Poku, E. K., Rockne, R. C., Shively, J. E., & Pichiorri, F. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251983 · Cited by 39
“Given the especially strong efficacy afforded by daratumumab with immunomodulatory drugs (lenalidomide and pomalidomide) (2–6), the use of daratumumab plus immunomodulatory drugs is now Food and Drug Administration–approved for advanced relapsed MM (2).”
BackgroundHarnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40
“Lenalidomide is also FDA approved post-ASCT as maintenance therapy as it prolongs both PFS and OS (123); in RRMM setting, it is FDA approved in combination with daratumumab (41), elotuzumab (31), ixazomib (124), and carfilzomib (125).”
BackgroundMRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Landgren, O., Lu, S. X., & Hultcrantz, M. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.03.001 · Cited by 37
Maiese, E. M., Ainsworth, C., Moine, J.-G. L., Ahdesmäki, O., Bell, J. A., & Hawe, E. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.014 · Cited by 35
Miguel, J. F. S., Usmani, S. Z., Mateos, M., van de Donk, N. W. C. J., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Liu, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243790 · Cited by 38
“Median (range) time to onset of IRRs was 70 (9-80) minutes.”
Self-citationDiamond, B. T., Rustad, E. H., Maclachlan, K. H., Thoren, K. L., Ho, C., Roshal, M., Ulaner, G. A., & Landgren, O. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100732 · Cited by 38
Fayon, M., Martínez-Cingolani, C., Abecassis, A., Roders, N., Nelson, E., Choisy, C., Talbot, A., Bensussan, A., Fermand, J., Arnulf, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.242453 · Cited by 36
“2 Monoclonal antibodies (mAb) targeting CD38, such as daratumumab, have shown good therapeutic efficacy in Multiple Myeloma (MM), both alone (1) and in combination with normal standard of care regimens (2, 3).”
BackgroundCastillo, J. J., Callander, N. S., Baljević, M., Sborov, D. W., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26155 · Cited by 40
Lu, J., Fu, W., Li, W., Hu, J., An, G., Wang, Y., Fu, C., Chen, L., Jin, J., Cen, X., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.04.012 · Cited by 38
Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 36
“This study was followed by the phase III POLLUX study evaluating lenalidomide and dexamethasone with or without daratumumab in patients with MM who received a least one prior line of therapy.(38) In this study, 569 patients who had received one or more prior lines of therapy received lenalidomide plus dexamethasone wi…”
MethodSelf-citationImmunologic approaches for the treatment of multiple myeloma
Rasche, L., Weinhold, N., Morgan, G. J., van Rhee, F., & Davies, F. E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.010 · Cited by 38
de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., Fernando, R. C., Sanson, L. F. G., de Carvalho, M. F., Braga, W. M. T., Davies, F. E., & Colleoni, G. W. B. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.016 · Cited by 36
Novel Immunotherapies for Multiple Myeloma
D’Agostino, M., Boccadoro, M., & Smith, E. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0397-7 · Cited by 37
Takamatsu, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6100091 · Cited by 40
“combination therapies using daratumumab, an anti-CD38 monoclonal antibody, were reported: the POLLUX study of daratumumab-lenalidomide-dexamethasone (DRd) [10] and the CASTOR study of daratumumab-bortezomib-dexamethasone (DVd) [11] for relapsed/refractory MM [50].”
MethodHMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
Guo, X., He, D., Zhang, E., Chen, J., Chen, Q., Li, Y., Yang, L., Yang, Y., Zhao, Y., Wang, G., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0883-3 · Cited by 36
Prognostic factors for multiple myeloma in the era of novel therapies
Ziogas, D. C., Dimopoulos, M. A., & Kastritis, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1537776 · Cited by 35
“2% in the daratumumab arm for the entire cohort [132], and improved PFS for patients with high-risk cytogenetics over Rd alone; however, their presence had a significant impact in the PFS of patients treated with the daratumumab, lenalidomide, and dexamethasone (DRd) triplet also [133].”
BackgroundSelf-citationImmunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
Castellà, M., de Larrea, C. F., & Martín-Antonio, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113613 · Cited by 37
“Monoclonal Antibodies CD38 Dara − FDA approved NCT00574288 NCT01985126 [17–19] Bort and Dex Phase III (Active, not recruiting) NCT02136134 [20,21] Len and Dex Phase III (Active, not recruiting) NCT02076009 [22,23]”
BackgroundBerenson, J. R., To, J., Spektor, T. M., Martinez, D., Turner, C., Sánchez, A., Ghermezi, M., Eades, B., Swift, R. A., Schwartz, G. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1899 · Cited by 36
“The most common grade 3 or higherAEswere anemia (18%), thrombocytopenia (14%), lymphopenia (14%), neutropenia (14%), pneumonia (11%), leukopenia (11%), sepsis (11%), and hypophosphatemia (7%; Table 2) with the rate of anemia and neutropenia being lower than the rates reported of 20% and 37%, respectively, in another c…”
ResultMilani, P., Fazio, F., Basset, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25828 · Cited by 36
Fu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.009 · Cited by 36
Daratumumab for the treatment of AL amyloidosis
Sidiqi, M. H., & Gertz, M. A. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485914 · Cited by 35
“With a median follow-up of 7.9 months median PFS was 9.5 months and median overall survival (OS) not reached.”
BackgroundInfluentialSong, X., Wilson, K. L., Kagan, J., & Panjabi, S. S. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719839025 · Cited by 36
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 40
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
Verkleij, C. P. M., Frerichs, K. A., Broekmans, M. E. C., Absalah, S., Maas-Bosman, P. W. C., Kruyswijk, S., Nijhof, I. S., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27792 · Cited by 35
Pathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33
Treatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 37
Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
Sherbenou, D. W., Mark, T. M., & Forsberg, P. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.030 · Cited by 36
“The POLLUX trial randomized 569 patients to Len/Dex/Dara or Len/Dex alone.(24) Again, the study was stopped after the prespecified interim analysis showed a hazard ratio for progression or”
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab
Kim, K., & Phelps, M. A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01240-8 · Cited by 35
“Infusion-related reactions were reported in 45% and 48% of patients receiving Dara-IV in CASTOR and POLLUX, respectively [5, 6].”
BackgroundNeri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 35
Self-citationBone marrow micro-environment is a crucial player for myelomagenesis and disease progression
Mondello, P., Cuzzocrea, S., Navarra, M., & Mian, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14610 · Cited by 34
“0001) and reduced the risk of disease progression of 63% [105].”
BackgroundMethodTreating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 35
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Perrot, A., Corre, J., & Avet‐Loiseau, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200879 · Cited by 34
Rocchi, S., Tacchetti, P., Pantani, L., Mancuso, K., Rizzello, I., Bezzi, C. D. G., Scalese, M., Dozza, L., Marzocchi, G., Martello, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2820 · Cited by 35
Verkleij, C. P. M., Jhatakia, A., Broekmans, M. E. C., Frerichs, K. A., Zweegman, S., Mutis, T., Bezman, N., & van de Donk, N. W. C. J. (2020) · Cancers · doi:10.3390/cancers12123713 · Cited by 35
Lee, J. Y., Ryu, D., Lim, S. W., Ryu, K. J., Choi, M. E., Yoon, S. E., Kım, K., Park, C., & Kim, S. J. (2021) · Journal of Cancer · doi:10.7150/jca.55553 · Cited by 35
“Despite significant advances in the treatment of MM, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, MM remains incurable because most patients experience recurrent relapse [3-7].”
BackgroundSelf-citationDavies, F. E., Rifkin, R. M., Costello, C. L., Morgan, G. J., Usmani, S. Z., Abonour, R., Palumbo, A. P., Romanus, D., Hájek, R., Terpos, E., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04534-8 · Cited by 34
Self-citationExperts’ consensus on the definition and management of high risk multiple myeloma
Marcon, C., Simeon, V., Deias, P., Facchin, G., Corso, A., Derudas, D., Montefusco, V., Offidani, M., Petrucci, M. T., Zambello, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1096852 · Cited by 37
“MRD negativity correlates with an improvement in outcome, in terms of PFS and OS (87) in several recent studies, both after first line treatment (69) and in relapsed or refractory MM (88, 89).”
ResultZhang, T., Wang, S., Wan, N., Zhang, L., Zhang, Z., & Jiang, J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.012 · Cited by 34
Jullien, M., Trudel, S., Tessoulin, B., Mahé, B., Dubruille, V., Blin, N., Gastinne, T., Bonnet, A., Lok, A., Lebourgeois, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03655-5 · Cited by 33
Self-citationBispecific Antibodies: A New Era of Treatment for Multiple Myeloma
Zhou, X., Einsele, H., & Danhof, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072166 · Cited by 33
“Consequently, daratumumab has become a standard of care in multiple myeloma [12,13].”
BackgroundMinařík, J., Pika, T., Radocha, J., Jungová, A., Štraub, J., Jelı́nek, T., Pour, L., Pavlíček, P., Mistrík, M., Brožová, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07732-1 · Cited by 33
Kaweme, N. M., Changwe, G. J., & Zhou, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.612696 · Cited by 35
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Minakata, D., Fujiwara, S., Yokoyama, D., Noguchi, A., Aoe, S., Oyama, T., Koyama, S., Murahashi, R., Nakashima, H., Hyodo, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18654 · Cited by 35
Jain, T., Sonbol, M. B., Firwana, B., Kolla, K. R., Almader‐Douglas, D., Palmer, J. M., & Fonseca, R. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.021 · Cited by 33
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies
McCullough, K. B., Hobbs, M., Abeykoon, J. P., & Kapoor, P. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0443-0 · Cited by 36
van de Donk, N. W. C. J., van der Holt, B., Minnema, M. C., Vellenga, E., Croockewit, S., Kersten, M. J., Borne, P. A. V. D., Ypma, P. F., Schaafsma, R., de Weerdt, O., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30149-2 · Cited by 33
Novellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 34
Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality
Costa, L. J., Godby, K. N., Chhabra, S., Cornell, R. F., Hari, P., & Bhatia, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.15426 · Cited by 32
Hagen, P. A., & Stiff, P. J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.002 · Cited by 32
Multiple Myeloma: Current Advances and Future Directions
Martin, T. G., & Huff, C. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.025 · Cited by 33
Immunotherapy in Hematologic Malignancies
Kansara, R. R., & Speziali, C. D. (2020) · Current Oncology · doi:10.3747/co.27.5117 · Cited by 32
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Fotiou, D., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000381 · Cited by 32
Self-citationDaratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
Chong, L. L., Soon, Y. Y., Soekojo, C. Y., Ooi, M. G. M., Chng, W. J., & Mel, S. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103211 · Cited by 32
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
Sanchez, L. J., Dardac, A., Madduri, D., Richard, S., & Richter, J. R. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989585 · Cited by 32
Minimal residual disease in multiple myeloma: current status
Ding, H., Xu, J., Lin, Z., Huang, J., Wang, F., Yang, Y., Cui, Y., Luo, H., Gao, Y., Zhai, X., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00328-2 · Cited by 35
Li, H., Li, F., Zhou, X., Mei, J.-G., Song, P., An, Z.-M., Zhao, Q., Guo, X., Wang, X., & Zhai, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03609-x · Cited by 32
Ntanasis‐Stathopoulos, I., Filippatos, C., Ntanasis‐Stathopoulos, A., Malandrakis, P., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., Terpos, E., & Gavriatopoulou, M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27582 · Cited by 32
Self-citationA question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 32
Self-citationXu, X. S., Dimopoulos, M. A., Sonneveld, P., Ho, P. J., Belch, A., Leiba, M., Capra, M., Gomez, D., Medvedova, E., Iida, S., et al. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0815-9 · Cited by 32
Self-citationTerpos, E., Kostopoulos, I. V., Kastritis, E., Ntanasis‐Stathopoulos, I., Migkou, M., Rousakis, P., Argyriou, A., Kanellias, N., Fotiou, D., Eleutherakis‐Papaiakovou, E., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000300 · Cited by 33
Self-citationPositron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
Sachpekidis, C., Goldschmidt, H., & Dimitrakopoulou‐Strauss, A. (2019) · Molecules · doi:10.3390/molecules25010134 · Cited by 31
Self-citationNK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
Shimizu, K., Iyoda, T., Yamasaki, S., Kadowaki, N., Tojo, A., & Fujii, S. (2020) · Cancers · doi:10.3390/cancers12040817 · Cited by 34
“9% (control group), respectively [138,139] (Table S1).”
Usmani, S. Z., Mateos, M., Hungria, V., Iida, S., Bahlis, N. J., Nahi, H., Magen, H., Cavo, M., Hulin, C., White, D. J., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03365-w · Cited by 31
Self-citationFacts and Hopes in Multiple Myeloma Immunotherapy
Sperling, A. S., & Anderson, K. C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3600 · Cited by 34
Bringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31
Self-citationCavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 32
“In a second phase 3 trial (POLLUX), patients with RRMM receiving DRd achieved a significantly longer PFS than those treated with Rd alone [97].”
Rosenberg, A. S. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2136950 · Cited by 31
“opment is associated with poorer outcomes [39].”
Mak, J. W. Y., Law, A. W. H., Law, K. W. T., Ho, R., Cheung, C. K. M., & Law, M. F. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4942 · Cited by 34
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 30
Trudel, S., Moreau, P., & Touzeau, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s174640 · Cited by 29
“For the treatment of patients with RRMM, lenalidomide has also been studied in combination with carfilzomib (KRd), ixazomib (IRd) and daratumumab (DaraRd).(8,33,35) In terms of response PFS, the triplet DaraRd led to better results in comparison with Elo-Rd, with similar safety profiles.”
BackgroundResultSelf-citationNovel Experimental Drugs for Treatment of Multiple Myeloma
Offidani, M., Corvatta, L., Morè, S., & Olivieri, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265288 · Cited by 32
Tan, K., Bryan, J., Segal, B. D., Bellomo, L. P., Nussbaum, N., Tucker, M., Torres, A. Z., Bennette, C., Capra, W. B., Curtis, M. D., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2351 · Cited by 32
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 31
“- Dara-Vd: N=143; - Dara-Rd: N=263 66-70 3 (2-11) Dara SA:”
InfluentialDaratumumab for POEMS Syndrome
Khan, M., Stone, K., & van Rhee, F. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.02.001 · Cited by 29
Suzuki, K., Dimopoulos, M. A., Takezako, N., Okamoto, S., Shinagawa, A., Matsumoto, M., Kosugi, H., Yoon, S., Huang, S., Qin, X., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0071-x · Cited by 30
Self-citationShould Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30
Zhu, Y., Zhang, Z., Jiang, Z., Liu, Y., & Zhou, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00369 · Cited by 29
“Because CD38 is uniformly and highly expressed on myeloma cells, a novel therapeutic strategy has emerged that involves targeting CD38 in multiple myeloma; basic research and clinical trials have demonstrated that antiCD38 mAbs (such as daratumumab) have high efficacy and favorable safety as immunotherapies to increas…”
BackgroundChimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Dhakal, B., Hari, P., Usmani, S. Z., & Hamadani, M. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01023-w · Cited by 29
“CD38 is another potential target for CAR-T in myeloma because of its high-intensity expression in plasma cells, and the astounding success of CD38 antibodies in myeloma therapeutics [5, 26].”
BackgroundSelf-citationCD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Jiao, Y., Yi, M., Xu, L., Chu, Q., Yan, Y., Luo, S., & Wu, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814253 · Cited by 29
Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
Suzuki, K., Nishiwaki, K., & Yano, S. (2021) · Cancers · doi:10.3390/cancers13020215 · Cited by 28
Self-citationWang, H., Fang, K., Yan, W., & Chang, X. (2021) · Journal of Innate Immunity · doi:10.1159/000516642 · Cited by 29
Hasegawa, K., Ikeda, S., Yaga, M., Watanabe, K., Urakawa, R., Iehara, A., Iwai, M., Hashiguchi, S., Morimoto, S., Fujiki, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7706 · Cited by 29
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 29
Yan, X., Clemens, P. L., Puchalski, T. A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Usmani, S. Z., Richardson, P. G. G., Plesner, T., Liu, K., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0598-1 · Cited by 30
“Daratumumab has been shown to provide clinical benefit for the treatment of multiple myeloma (MM) in patients with one or more prior line of therapy [8, 9].”
BackgroundSelf-citationMinimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Harousseau, J., & Avet‐Loiseau, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.1331 · Cited by 28
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
Kaur, J., Valisekka, S. S., Hameed, M., Bandi, P. S., Varma, S., Onwughalu, C. J., Ibrahim, H., & Mongia, H. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.004 · Cited by 29
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
Tzogani, K., Penninga, E. I., Christiansen, M. L. S., Hovgaard, D., Sarac, S. B., Jiménez, J. C., Garcia, I., Lafuente, M., Sancho-López, A., Salmonson, T., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0328 · Cited by 28
“lenalidomide and low-dose dexamethasone (DRd), with lenalidomide and low-dose dexamethasone (Rd) in 569 patients with relapsed or refractory MM [14].”
BackgroundVariable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)
Cleynen, A., Samur, M., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-09-876433 · Cited by 28
Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02715-w · Cited by 28
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
Nishida, H., & Yamada, T. (2019) · Journal of Oncology · doi:10.1155/2019/6084012 · Cited by 28
“Phase III POLLUX trials demonstrated remarkable efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) in patients with RRMM [33, 34].”
BackgroundUse of daratumumab in high risk multiple myeloma: A meta‐analysis
Premkumar, V. J., Pan, S. M., Lentzsch, S., & Bhutani, D. (2020) · eJHaem · doi:10.1002/jha2.47 · Cited by 27
“The MAIA, ALCYONE, CASTOR and POLLUX trials were sponsored by Janssen Research and Development and independent ethics committees or institutional review boards at each site approved the protocol.”
MethodInfluentialDaratumumab: A review of current indications and future directions
Hill, E., Morrison, C., & Kazandjian, D. G. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.008 · Cited by 28
Leleu, X. P., Gay, F., Flament, A., Allcott, K., & Delforge, M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3191-7 · Cited by 28
Avet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 26
Metadata
- Authors
- Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N. Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., & Moreau, P.
- Affiliations
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1319-1331
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528329272
- Cited by
- 1,445
- References
- 32
- Citations by year
- 2026: 50 · 2025: 78 · 2024: 78 · 2023: 108 · 2022: 138 · 2021: 221 · 2020: 236 · 2019: 175 · 2018: 193 · 2017: 148 · 2016: 15
- FWCI
- 168.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals
- Celgene
- Incyte
- Otsuka Pharmaceutical
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- daratumumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, thrombocytopenia, adverse events, monoclonal antibody therapy, combination therapy, overall response rate, safety and tolerability
- MeSH terms
- Lenalidomide, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
